Future of the Anti-Neoplastic Agents Market: Strategic Analysis and Forecast to 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Anti-Neoplastic Agents Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the anti-neoplastic agents market has seen impressive growth. The market size is projected to increase from $130.01 billion in 2024 to $140.9 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.4%. Factors contributing to the growth during the historical period include a surge in cancer cases, an uptick in demand for treatment options, a growing preference for minimally invasive cancer treatments, and the need for cost-effective anti-neoplastic therapies.

Anti-Neoplastic Agents Market Size Forecast: What's the Projected Valuation by 2029?
The market for anti-neoplastic agents is predicted to witness robust expansion in the coming years, reaching a valuation of "$197.68 billion in 2029, representing a compound annual growth rate (CAGR) of 8.8%. The projected increase during this period is due to factors such as heightened awareness and knowledge about the condition among patients, governmental initiatives, surging demand for tailor-made cancer therapy, and an increased emphasis on life quality during cancer treatment. The primary trends expected during this forecast period encompass progress in oncology research, the creation of specifically-targeted treatments, innovative breakthroughs in biotechnology, and advancements in diagnostic tools.

View the full report here:
https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

What Are the Drivers Transforming the Anti-Neoplastic Agents Market?
The rise in cancer incidences is predicted to fuel the expansion of the antineoplastic agent market. Cancer encompasses a range of diseases that can originate from almost any organ or tissue when cells behave abnormally, multiply without control, breach their usual confines and either metastasize to other organs or impinge on adjacent body parts. Antineoplastic agents are crucial in cancer treatment because they inhibit the growth and division of cancer cells using various strategies, such as causing DNA damage, disrupting the cell cycle, and meddling with critical cellular pathways. For example, in February 2024, the International Agency for Research on Cancer (IARC), a French international agency that fosters global cooperation in cancer research, estimated that the global cancer burden would escalate to over 35 million by 2050, a 77% surge from the projected 20 million in 2022. Consequently, the escalating cancer incidence is powering the expansion of the antineoplastic agent market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12901&type=smp

What Trends Will Shape the Anti-Neoplastic Agents Market Through 2029 and Beyond?
Leading companies in the anti-neoplastic agent market are striving to create sustainable clinical practices to maintain their hold on the market. As an example, Novartis AG, the pharmaceutical corporation from Switzerland, announced in March 2022 that the Food and Drug Administration (FDA) has given approval to Pluvicto, its first therapy targeted at radioligand for treating progressive, Prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC). The recommendation is for the administration of 7.4 GBq (200 mCi) of Pluvicto intravenously every six weeks, up to a maximum of six doses. This protocol is to be followed until either the disease progresses or the toxicity becomes intolerable. For this treatment, patients with previously treated mCRPC should be selected based on their tumor's PSMA expression, using Locametz or another authorized PSMA-11 imaging agent.

Which Segments in the Anti-Neoplastic Agents Market Offer the Most Profit Potential?
The anti-neoplastic agents market covered in this report is segmented -

1) By Type: Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous
2) By Disease Type: Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Other Disease Types
3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Subsegments:
1) By Alkylating Agents: Nitrogen Mustards, Alkyl Sulfonates, Nitrosoureas, Triazines
2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues, Folate Antagonists
3) By Hormones and Antagonists: Estrogens and Antiestrogens, Androgens and Antiandrogens, Glucocorticoids
4) By Miscellaneous: Vinca Alkaloids, Taxanes, Antibiotic Antineoplastics, Targeted Therapy Agents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12901&type=smp

Which Firms Dominate the Anti-Neoplastic Agents Market by Market Share and Revenue in 2025?
Major companies operating in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.

Which Regions Offer the Highest Growth Potential in the Anti-Neoplastic Agents Market?
North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12901

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.